Marlies S Wijsenbeek

List of Publications by Year in Descending Order

97 papers	2,189 citations	27 h-index	43 g-index
114 ext. papers	3,585 ext. citations	9.6 avg, IF	5.41 L-index

#	Paper	IF	Citations
97	Comprehensive Care of Interstitial Lung Disease **2022**, 64-78		
96	Non-organ-specific manifestations of sarcoidosis **2022**, 206-222		
95	PAciFy Cough-a multicentre, double-blind, placebo-controlled, crossover trial of morphine sulphate for the treatment of pulmonary Fibrosis Cough.. *Trials*, **2022**, 23, 184	2.8	0
94	The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry.. *Respiratory Medicine*, **2022**, 196, 106801	4.6	2
93	Idiopathic Pulmonary Fibrosis (an Update) and Progressive Pulmonary Fibrosis in Adults: An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.. *American Journal of Respiratory and Critical Care Medicine*, **2022**, 205, e18-e47	10.2	38
92	Antacid Medication and Antireflux Surgery in Patients with Idiopathic Pulmonary Fibrosis: A Systematic Review and Meta-Analysis.. *Annals of the American Thoracic Society*, **2022**, 19, 833-844	4.7	2
91	Exhaled breath analysis by use of eNose technology: a novel diagnostic tool for interstitial lung disease. *European Respiratory Journal*, **2021**, 57,	13.6	7
90	Educational aspects of rare and orphan lung diseases. *Respiratory Research*, **2021**, 22, 92	7.3	5
89	Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseases. *Respiratory Research*, **2021**, 22, 84	7.3	11
88	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. *European Respiratory Review*, **2021**, 30,	9.8	2
87	Management of Idiopathic Pulmonary Fibrosis. *Clinics in Chest Medicine*, **2021**, 42, 275-285	5.3	2
86	Disease Behaviour During the Peri-Diagnostic Period in Patients with Suspected Interstitial Lung Disease: The STARLINER Study. *Advances in Therapy*, **2021**, 38, 4040-4056	4.1	0
85	COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes. *Current Opinion in Pulmonary Medicine*, **2021**, 27, 463-471	3	1
84	Feasibility of online home spirometry in systemic sclerosis-associated interstitial lung disease: a pilot study. *Rheumatology*, **2021**, 60, 2467-2471	3.9	1
83	Patient reported side-effects of prednisone and methotrexate in a real-world sarcoidosis population. *Chronic Respiratory Disease*, **2021**, 18, 14799731211031935	3	1
82	The Value of the Surprise Question to Predict One-Year Mortality in Idiopathic Pulmonary Fibrosis: A Prospective Cohort Study. *Respiration*, **2021**, 100, 780-785	3.7	1
81	Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. *Journal of Heart and Lung Transplantation* , **2021**, 40, 1349-1379	5.8	34

80	Patient-centered Outcomes Research in Interstitial Lung Disease: An Official American Thoracic Society Research Statement. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, e3-e23	10.2	1
79	The use of online visual analogue scales in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2021**,	13.6	0
78	Patient Reported Experiences and Delays During the Diagnostic Pathway for Pulmonary Fibrosis: A Multinational European Survey. *Frontiers in Medicine*, **2021**, 8, 711194	4.9	0
77	Early diagnosis of fibrotic interstitial lung disease: challenges and opportunities. *Lancet Respiratory Medicine,the*, **2021**, 9, 1065-1076	35.1	7
76	Palliative Care in Interstitial Lung Disease. *Respiratory Medicine*, **2021**, 189-207	0.2	
75	Home spirometry in patients with idiopathic pulmonary fibrosis: data from the INMARK trial. *European Respiratory Journal*, **2021**, 58,	13.6	2
74	Comparison of the treatment guidelines for sarcoidosis: common sense in the search for evidence.. *European Respiratory Journal*, **2021**,	13.6	
73	Progress in the treatment of pulmonary fibrosis. *Lancet Respiratory Medicine,the*, **2020**, 8, 424-425	35.1	5
72	Desquamative interstitial pneumonia: a systematic review of its features and outcomes. *European Respiratory Review*, **2020**, 29,	9.8	15
71	Comprehensive Care for Patients with Sarcoidosis. *Journal of Clinical Medicine*, **2020**, 9,	5.1	14
70	Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. *European Respiratory Journal*, **2020**, 55,	13.6	18
69	Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS trials. *Respiratory Research*, **2020**, 21, 36	7.3	13
68	Home Monitoring in Patients with Idiopathic Pulmonary Fibrosis. A Randomized Controlled Trial. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 393-401	10.2	28
67	Diurnal variation in forced vital capacity in patients with fibrotic interstitial lung disease using home spirometry. *ERJ Open Research*, **2020**, 6,	3.5	5
66	The effect of the walk-bike on quality of life and exercise capacity in patients with idiopathic pulmonary fibrosis: a feasibility study. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2020**, 37, 192-202	1.1	2
65	Managing Fatigue in Patients With Interstitial Lung Disease. *Chest*, **2020**, 158, 2026-2033	5.3	6
64	Idiopathic Pulmonary Fibrosis: Best Practice in Monitoring and Managing a Relentless Fibrotic Disease. *Respiration*, **2020**, 99, 73-82	3.7	30
63	Design of a randomized controlled trial to evaluate effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis: the PREDMETH study. *BMC Pulmonary Medicine*, **2020**, 20, 271	3.5	7

62	Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. *Respiratory Research*, **2020**, 21, 312	7.3	10
61	Evaluation of a Home Monitoring Application for Follow Up after Lung Transplantation-A Pilot Study. *Journal of Personalized Medicine*, **2020**, 10,	3.6	2
60	Patient expectations, experiences and satisfaction with nintedanib and pirfenidone in idiopathic pulmonary fibrosis: a quantitative study. *Respiratory Research*, **2020**, 21, 196	7.3	5
59	The need for a holistic approach for SSc-ILD - achievements and ambiguity in a devastating disease. *Respiratory Research*, **2020**, 21, 197	7.3	13
58	Spectrum of Fibrotic Lung Diseases. *New England Journal of Medicine*, **2020**, 383, 958-968	59.2	102
57	Gender equity in interstitial lung disease. *Lancet Respiratory Medicine,the*, **2020**, 8, 842-843	35.1	2
56	Modelling Forced Vital Capacity in Idiopathic Pulmonary Fibrosis: Optimising Trial Design. *Advances in Therapy*, **2019**, 36, 3059-3070	4.1	1
55	The impact of the new Global Lung Function Initiative reference values on trial inclusion for patients with idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2019**, 53,	13.6	5
54	Design of a Study Assessing Disease Behaviour During the Peri-Diagnostic Period in Patients with Interstitial Lung Disease: The STARLINER Study. *Advances in Therapy*, **2019**, 36, 232-243	4.1	9
53	Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2). *BMJ Open Respiratory Research*, **2019**, 6, e000422	5.6	50
52	Feasibility of a Comprehensive Home Monitoring Program for Sarcoidosis. *Journal of Personalized Medicine*, **2019**, 9,	3.6	14
51	Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 152-159	10.2	25
50	Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. *Respiratory Medicine*, **2019**, 150, 120-125	4.6	2
49	Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. *Current Medical Research and Opinion*, **2019**, 35, 2015-2024	2.5	65
48	First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. *BMJ Open Respiratory Research*, **2019**, 6, e000394	5.6	9
47	Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. *Lancet Respiratory Medicine,the*, **2019**, 7, 657-664	35.1	42
46	Diagnostic Likelihood Thresholds That Define a Working Diagnosis of Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1146-1153	10.2	33
45	Enhanced Bruton's tyrosine kinase in B-cells and autoreactive IgA in patients with idiopathic pulmonary fibrosis. *Respiratory Research*, **2019**, 20, 232	7.3	11

44	Trafficking and lysosomal storage disorders **2019**, 319-332		
43	Research highlights from the 2018 ERS International Congress: interstitial lung diseases. *ERJ Open Research*, **2019**, 5,	3.5	2
42	Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. *ERJ Open Research*, **2019**, 5,	3.5	4
41	Cardiovascular safety of nintedanib in subgroups by cardiovascular risk at baseline in the TOMORROW and INPULSIS trials. *European Respiratory Journal*, **2019**, 54,	13.6	16
40	Gaps in care of patients living with pulmonary fibrosis: a joint patient and expert statement on the results of a Europe-wide survey. *ERJ Open Research*, **2019**, 5,	3.5	17
39	Cough, an unresolved problem in interstitial lung diseases. *Current Opinion in Supportive and Palliative Care*, **2019**, 13, 143-151	2.6	2
38	The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. *European Respiratory Journal*, **2019**, 53,	13.6	30
37	Validity of the Patient Experiences and Satisfaction with Medications (PESaM) Questionnaire. *Patient*, **2019**, 12, 149-162	3.7	8
36	Nintedanib in Idiopathic Pulmonary Fibrosis: Practical Management Recommendations for Potential Adverse Events. *Respiration*, **2019**, 97, 173-184	3.7	27
35	Increased T-helper 17.1 cells in sarcoidosis mediastinal lymph nodes. *European Respiratory Journal*, **2018**, 51,	13.6	48
34	Statin Therapy and Outcomes in Trials of Nintedanib in Idiopathic Pulmonary Fibrosis. *Respiration*, **2018**, 95, 317-326	3.7	29
33	Development and feasibility of an eHealth tool for idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2018**, 51,	13.6	9
32	Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. *European Respiratory Journal*, **2018**, 51,	13.6	24
31	Th17-lineage cells in pulmonary sarcoidosis and Sjögren's syndrome: Friend or foe?. *Journal of Autoimmunity*, **2018**, 87, 82-96	15.5	22
30	Identifying Barriers to Idiopathic Pulmonary Fibrosis Treatment: A Survey of Patient and Physician Views. *Respiration*, **2018**, 96, 514-524	3.7	27
29	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis: An International Modified Delphi Survey. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 197, 1036-1044	10.2	109
28	No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. *Respiratory Medicine*, **2018**, 138S, S31-S37	4.6	27
27	Effect of Recombinant Human Pentraxin 2 vs Placebo on Change in Forced Vital Capacity in Patients With Idiopathic Pulmonary Fibrosis: A Randomized Clinical Trial. *JAMA - Journal of the American Medical Association*, **2018**, 319, 2299-2307	27.4	107

26	Safety of nintedanib added to pirfenidone treatment for idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2018**, 52,	13.6	53
25	Optimizing quality of life in patients with idiopathic pulmonary fibrosis. *Therapeutic Advances in Respiratory Disease*, **2017**, 11, 157-169	4.9	49
24	Translation and validation of the Kings's Brief Interstitial Lung Disease (K-BILD) questionnaire in French, Italian, Swedish, and Dutch. *Chronic Respiratory Disease*, **2017**, 14, 140-150	3	10
23	What patients with pulmonary fibrosis and their partners think: a live, educative survey in the Netherlands and Germany. *ERJ Open Research*, **2017**, 3,	3.5	20
22	Patient and partner empowerment programme for idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2017**, 49,	13.6	14
21	Development and Pretesting of a Questionnaire to Assess Patient Experiences and Satisfaction with Medications (PESaM Questionnaire). *Patient*, **2017**, 10, 629-642	3.7	12
20	Palliative care in interstitial lung disease: living well. *Lancet Respiratory Medicine,the*, **2017**, 5, 968-980	35.1	115
19	Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2017**, 50,	13.6	37
18	Diagnostic accuracy of a clinical diagnosis of idiopathic pulmonary fibrosis: an international case-cohort study. *European Respiratory Journal*, **2017**, 50,	13.6	50
17	A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomised, double-blind, proof-of-concept, phase 2 trial. *Lancet Respiratory Medicine,the*, **2017**, 5, 806-815	35.1	71
16	Integrating Patient Perspectives into Personalized Medicine in Idiopathic Pulmonary Fibrosis. *Frontiers in Medicine*, **2017**, 4, 226	4.9	18
15	European idiopathic pulmonary fibrosis Patient Charter: a missed opportunity. *European Respiratory Journal*, **2016**, 48, 283-4	13.6	4
14	New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?. *Current Opinion in Pulmonary Medicine*, **2016**, 22, 434-41	3	15
13	Acetylcysteine in IPF: the knockout blow?. *Lancet Respiratory Medicine,the*, **2016**, 4, 420-1	35.1	7
12	Recombinant human pentraxin-2 therapy in patients with idiopathic pulmonary fibrosis: safety, pharmacokinetics and exploratory efficacy. *European Respiratory Journal*, **2016**, 47, 889-97	13.6	54
11	European IPF Patient Charter: unmet needs and a call to action for healthcare policymakers. *European Respiratory Journal*, **2016**, 47, 597-606	13.6	71
10	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis: methodological concerns. *European Respiratory Journal*, **2016**, 48, 1524-1526	13.6	16
9	Medical Therapy in Idiopathic Pulmonary Fibrosis. *Seminars in Respiratory and Critical Care Medicine*, **2016**, 37, 368-77	3.9	17

8	Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2016**, 47, 1776-84	13.6	43
7	Cough in idiopathic pulmonary fibrosis. *European Respiratory Review*, **2016**, 25, 278-86	9.8	62
6	Early Experience of Pirfenidone in Daily Clinical Practice in Belgium and The Netherlands: a Retrospective Cohort Analysis. *Advances in Therapy*, **2015**, 32, 691-704	4.1	24
5	Treatment of Sarcoidosis. *Clinics in Chest Medicine*, **2015**, 36, 751-67	5.3	42
4	Cultural Differences in Palliative Care in Patients With Idiopathic Pulmonary Fibrosis. *Chest*, **2015**, 148, e56	5.3	13
3	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. *BioMed Research International*, **2015**, 2015, 329481	3	44
2	Challenges in the classification of fibrotic ILD: Patient case 2. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2015**, 32 Suppl 1, 13-6	1.1	
1	Safety and efficacy of ustekinumab or golimumab in patients with chronic sarcoidosis. *European Respiratory Journal*, **2014**, 44, 1296-307	13.6	126